|Other Names||Receptor-type tyrosine-protein phosphatase-like N, R-PTP-N, Islet cell antigen 512, ICA 512, Islet cell autoantigen 3, PTP IA-2, PTPRN, ICA3, ICA512|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8428a was selected from the N-term region of human PTPIA2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Implicated in neuroendocrine secretory processes. May be involved in processes specific for neurosecretory granules, such as their biogenesis, trafficking or regulated exocytosis or may have a general role in neuroendocrine functions. Seems to lack intrinsic enzyme activity. May play a role in the regulation of secretory granules via its interaction with SNTB2.|
|Cellular Location||Membrane; Single-pass type I membrane protein. Note=Neuroendocrine secretory granules|
|Tissue Location||Expression is restricted to neuroendocrine cells. Found in pancreas, brain and pituitary|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PTPIA2 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and a single catalytic domain, and thus represents a receptor-type PTP. This PTP was found to be an autoantigen that is reactive with insulin-dependent diabetes mellitus (IDDM) patient sera, and thus may be a potential target of autoimmunity in diabetes mellitus.
Miao, D., et al., J. Autoimmun. 18(2):191-196 (2002).Cui, L., et al., J. Biol. Chem. 271(40):24817-24823 (1996).Lan, M.S., et al., DNA Cell Biol. 13(5):505-514 (1994).Rabin, D.U., et al., J. Immunol. 152(6):3183-3188 (1994).Mikulecky, M., et al., Biomed. Pharmacother. 55 Suppl 1, 106S-109S (2001).
If you have any additional inquiries please email technical services at email@example.com.